Schrödinger Receives $111.3 Million Distribution from Sale of Nimbus’s TYK2 Inhibitor to Takeda
Expects to Receive an Additional Distribution of Approximately
Schrödinger expects to report the first cash distribution as a gain on equity investments in the company’s first quarter 2023 financial statements. Schrödinger expects to receive a second distribution of approximately
“We began our journey with Nimbus at its founding in 2009 and we are delighted to see NDI-034858 partnered with Takeda and advancing toward pivotal trials,” stated
“The acquisition of NDI-034858 underscores the advantage of leveraging cutting-edge computation at scale, and we are proud to have Schrödinger as a partner,” said
Since Nimbus was founded, Schrödinger and Nimbus have collaborated on several programs, including the ACC inhibitor program that Gilead Sciences, Inc. acquired from Nimbus in 2016. As of
Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based computational platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Schrödinger’s multidisciplinary drug discovery team also leverages the software platform to advance a portfolio of collaborative and proprietary programs to address unmet medical needs.
Founded in 1990, Schrödinger has more than 800 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including but not limited to those regarding the potential advantages of our computational platform, the therapeutic potential and favorable properties of NDI-034858, our expectation for an additional cash distribution from Nimbus in connection with Takeda’s acquisition of NDI-034858, our expectations regarding the impact of the distribution from Nimbus on our first quarter 2023 financial results, and our expectations related to the use of our cash, cash equivalents and marketable securities. Statements including words such as “aim,” "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," “goal,” "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would" and statements in the future tense are forward-looking statements. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Actual results may differ materially from those described in the forward-looking statements and are subject to a variety of assumptions, uncertainties, risks and factors that are beyond our control, including our ability to further develop our computational platform, our reliance upon our third-party drug discovery collaborators, and other risks detailed under the caption "Risk Factors" and elsewhere in our
Source: Schrödinger Inc.